Active agent against cancer metastasis discovered: Adhibin prevents migration and attachment to other cells
Every cell in the body normally has its fixed place as part of a tissue structure. Except for a few cell types, such as blood ...
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...
precisionmedicineonline23h
Merck Talks Up Pipeline Diversification as Demand for Keytruda, Facing Patent Expirations, Grows
The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.
Metastatic cancers: Targeting a protein that fuels treatment-resistant tumors may be key to better outcomes
One of the biggest challenges in cancer treatment is addressing the ability of cancer cells to adapt and become resistant, ...
On World Cancer Day: City of Hope Offers 10 Bold Solutions to End Cancer
City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World ...
The reason young women’s bodies are more prone to cancer
Cancer is affecting increasing numbers of young women with the hormone oestrogen thought to play to a central role ...
Hosted on MSN1d
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...
Cancer patient's treatment was delayed - coroner
A coroner found there were "missed opportunities" to treat a 38-year-old woman with cancer. Carla Smith, 38, who died on 7 ...